Disaggregation of Hepatobiliary Cancer Mortality Among Asian Americans: Analysis of NVSS Mortality Data

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-09-29 DOI:10.1002/cam4.71259

Anna Park, Andrew Vodinh-Ho, Ivory Rok, Xinran Qi, George A. Hung, Nicholas Kikuta, Armaan Jamal, Gloria S. Kim, Latha P. Palaniappan, Malathi Srinivasan, Robert J. Huang, Adrian M. Bacong

{"title":"Disaggregation of Hepatobiliary Cancer Mortality Among Asian Americans: Analysis of NVSS Mortality Data","authors":"Anna Park, Andrew Vodinh-Ho, Ivory Rok, Xinran Qi, George A. Hung, Nicholas Kikuta, Armaan Jamal, Gloria S. Kim, Latha P. Palaniappan, Malathi Srinivasan, Robert J. Huang, Adrian M. Bacong","doi":"10.1002/cam4.71259","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Asian Americans (AAs) are a diverse population, and aggregation of AA health data in national reports conceals significant differences between AA subgroups. As hepatobiliary cancer rates increase globally, a greater understanding of hepatobiliary mortality among AA subgroups could motivate precision intervention and screening programs.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using national mortality data from 2005 to 2020, we report age-adjusted mortality rates, standardized mortality ratios, and annual percent change for hepatocellular carcinoma (HCC), nonspecified liver cancer (NOS), intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC) using national mortality data for the six largest AA subgroups (Asian Indian, Chinese, Filipino, Japanese, Korean, and Vietnamese) compared to non-Hispanic White people (NHW).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>All AA subgroups (except Asian Indians) had significantly higher hepatobiliary cancer mortality than NHW people. Vietnamese people demonstrated the highest mortality from HCC (7.65 per 100,000) and nonspecified liver cancer (5.57 per 100,000), while Korean people had the highest mortality from the biliary tract cancers: ICC (3.10 per 100,000), GBC (0.72 per 100,000), and ECC (0.97 per 100,000). Notably, ICC mortality increased across the study period. Across all subgroups, male individuals had significantly higher hepatobiliary cancer mortality than female individuals, with differences being largest for HCC and nonspecified liver cancer.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Differences in mortality across hepatobiliary cancer types demonstrate the importance of analyzing subtypes separately. These differences also highlight the importance of developing ethnically targeted screening, prevention strategies, and treatment.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477800/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71259","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Asian Americans (AAs) are a diverse population, and aggregation of AA health data in national reports conceals significant differences between AA subgroups. As hepatobiliary cancer rates increase globally, a greater understanding of hepatobiliary mortality among AA subgroups could motivate precision intervention and screening programs.

Methods

Using national mortality data from 2005 to 2020, we report age-adjusted mortality rates, standardized mortality ratios, and annual percent change for hepatocellular carcinoma (HCC), nonspecified liver cancer (NOS), intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC) using national mortality data for the six largest AA subgroups (Asian Indian, Chinese, Filipino, Japanese, Korean, and Vietnamese) compared to non-Hispanic White people (NHW).

Results

All AA subgroups (except Asian Indians) had significantly higher hepatobiliary cancer mortality than NHW people. Vietnamese people demonstrated the highest mortality from HCC (7.65 per 100,000) and nonspecified liver cancer (5.57 per 100,000), while Korean people had the highest mortality from the biliary tract cancers: ICC (3.10 per 100,000), GBC (0.72 per 100,000), and ECC (0.97 per 100,000). Notably, ICC mortality increased across the study period. Across all subgroups, male individuals had significantly higher hepatobiliary cancer mortality than female individuals, with differences being largest for HCC and nonspecified liver cancer.

Conclusions

Differences in mortality across hepatobiliary cancer types demonstrate the importance of analyzing subtypes separately. These differences also highlight the importance of developing ethnically targeted screening, prevention strategies, and treatment.

Abstract Image

查看原文本刊更多论文

亚裔美国人肝癌死亡率的分类：NVSS死亡率数据分析。

背景：亚裔美国人（AA）是一个多元化的人群，国家报告中汇总的AA健康数据掩盖了AA亚群之间的显著差异。随着全球范围内胆道癌发病率的上升，对AA亚组中胆道死亡率的更深入了解可以促进精确的干预和筛查计划。方法:使用2005年至2020年的全国死亡率数据，我们报告了肝细胞癌（HCC）、非特异性肝癌（NOS）、肝内胆管癌（ICC）、肝外胆管癌（ECC）和胆囊癌（GBC）的年龄调整死亡率、标准化死亡率和年百分比变化，使用六个最大的AA亚群（亚洲印度人、中国人、菲律宾人、日本人、韩国人和越南人）与非西班牙裔白人（NHW）相比的国家死亡率数据。结果：所有AA亚组（亚洲印第安人除外）的肝癌死亡率均显著高于NHW人群。越南的HCC（7.65 / 10万）和非特异性肝癌（5.57 / 10万）的死亡率最高，而韩国的胆道癌（ICC）（3.10 / 10万）、GBC（0.72 / 10万）、ECC（0.97 / 10万）的死亡率最高。值得注意的是，在整个研究期间，ICC死亡率有所增加。在所有亚组中，男性个体的肝胆癌死亡率明显高于女性个体，HCC和非特异性肝癌的差异最大。结论：不同类型肝癌死亡率的差异表明了单独分析亚型的重要性。这些差异也突出了制定针对种族的筛查、预防策略和治疗的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.